Pasithea Therapeutics Corp (KTTA) - Total Assets
Based on the latest financial reports, Pasithea Therapeutics Corp (KTTA) holds total assets worth $13.63 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Pasithea Therapeutics Corp - Total Assets Trend (2020–2024)
This chart illustrates how Pasithea Therapeutics Corp's total assets have evolved over time, based on quarterly financial data. Also see market cap of Pasithea Therapeutics Corp for the company's overall valuation and market capitalisation.
Pasithea Therapeutics Corp - Asset Composition Analysis
Current Asset Composition (December 2024)
Pasithea Therapeutics Corp's total assets of $13.63 Million consist of 45.9% current assets and 54.1% non-current assets. Review debt load of Pasithea Therapeutics Corp to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 43.1% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $7.31 Million | 45.5% |
| Goodwill | $1.26 Million | 7.9% |
Asset Composition Trend (2020–2024)
This chart illustrates how Pasithea Therapeutics Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Pasithea Therapeutics Corp (KTTA) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pasithea Therapeutics Corp's current assets represent 45.9% of total assets in 2024, a decrease from 100.0% in 2020.
- Cash Position: Cash and equivalents constituted 43.1% of total assets in 2024, down from 98.3% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 52.0% of total assets, an increase from 0.0% in 2020.
- Asset Diversification: The largest asset category is intangible assets at 45.5% of total assets.
Pasithea Therapeutics Corp Competitors by Total Assets
Key competitors of Pasithea Therapeutics Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B
|
Denmark | Dkr9.17 Billion |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
USA | $890.92 Million |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278
|
China | CN¥3.21 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF3.09 Billion |
|
Soleno Therapeutics Inc
NASDAQ:SLNO
|
USA | $608.39 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Inhibrx Biosciences, Inc.
NASDAQ:INBX
|
USA | $183.97 Million |
|
Wuhan Keqian Biology Co Ltd
SHG:688526
|
China | CN¥4.75 Billion |
Pasithea Therapeutics Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.02 | 14.81 | 37.55 |
| Quick Ratio | 4.02 | 14.81 | 37.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $4.15 Million | $9.12 Million | $241.35K |
Pasithea Therapeutics Corp - Advanced Valuation Insights
This section examines the relationship between Pasithea Therapeutics Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.39 |
| Latest Market Cap to Assets Ratio | 0.71 |
| Asset Growth Rate (YoY) | -38.5% |
| Total Assets | $16.06 Million |
| Market Capitalization | $11.35 Million USD |
Valuation Analysis
Below Book Valuation: The market values Pasithea Therapeutics Corp's assets below their book value (0.71x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Pasithea Therapeutics Corp's assets decreased by 38.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Pasithea Therapeutics Corp (2020–2024)
The table below shows the annual total assets of Pasithea Therapeutics Corp from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $16.06 Million | -38.49% |
| 2023-12-31 | $26.12 Million | -42.19% |
| 2022-12-31 | $45.18 Million | -15.27% |
| 2021-12-31 | $53.32 Million | +21403.88% |
| 2020-12-31 | $247.96K | -- |
About Pasithea Therapeutics Corp
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1);… Read more